30 Metabolomics and Type 2 Diabetes Mellitus Metabolomics uses tools such as nuclear magnetic resonance and mass spectroscopy to identify and quantitate large numbers of small-molecule products of metabolism. “Targeted” metabolomic studies are limited to a certain category of metabolites of interest (e.g. amino acids). In the field of DM, metabolomics

has helped identify novel risk factors for DM, which may be useful biomarkers for early DM risk31,32 and may also serve as clues to increase understanding of the complex pathophysiology of DM2. Analysis of many metabolites in baseline samples from large prospective population studies, such as the Framingham Heart Study, has identified strong independent Inhibitors,research,lifescience,medical predictive relationships between levels of branched-chain and aromatic amino acids (isoleucine, leucine, valine, tyrosine, and phenylalanine) and risk of DM incidence over 12 years.31 Further studies in this population identified a Inhibitors,research,lifescience,medical novel metabolite (2-aminoadipic acid) which is independently predictive of DM risk, pointing to a potential different pathophysiologic pathway underlying Inhibitors,research,lifescience,medical DM.33 The field of “lipidomics” employs the analytic technology and large data

set approach of metabolomics to study variations in lipid structures. Using the same Framingham Heart Study population, Rhee et al. found that shorter triacylglycerol fatty acid chain length and lower Inhibitors,research,lifescience,medical double-bond content reflect insulin resistance and serve as an independent marker of DM risk.34 The potential role of metabolomic studies in DM

research and practice has CI-1040 cell line recently been reviewed.35,36 Pharmacogenomics and Type 2 Diabetes Mellitus Pharmacogenomics studies the effect of genetic variations on drug kinetics or action. Genetically determined differences in absorption or metabolism of an agent, or variation in tissue responsiveness, may increase or decrease the effectiveness Inhibitors,research,lifescience,medical or side effects of a drug in a clinically important manner. Pharmacogenomic advances have the potential to improve the effectiveness and safety of oral anti-diabetic therapy37,38 but have not yet reached the stage of wide clinical applicability. This is in contrast to the field of antithrombotic therapy where variants in the CYP2C19 enzyme, which affect hepatic activation of the widely used anti-platelet Farnesyltransferase agent clopidogrel, may result in clinically relevant reduction in drug effectiveness. Genetic testing for this variant is available, but its role in routine practice remains controversial.39 In the case of metformin, the most widely used drug for DM2, recent findings of the role of organic cationic transporter proteins in the mechanism of action of metformin led to the discovery that variants related to the genes for these transporter proteins may reduce metformin effectiveness40 and tolerance.